Achieve is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years.
It is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase 3 clinical trials in Europe and New Zealand. Achieve initiated a Phase 2b Optimization Trial (ORCA-1) evaluating cytisinicline in the United States and reported results in June 2019. The Phase 3 cytisinicline development program is expected to begin in 2020.
Achieve’s focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. Smoking is currently the leading cause of preventable death and is responsible for nearly six million people losing their lives annually worldwide.